Ventilator-Associated Pneumonia Management Strategies

Ventilator-associated pneumonia (VAP) remains one of the most serious complications in mechanically ventilated patients, contributing to prolonged intensive care stays, increased mortality and substantial healthcare costs. Management strategies span prevention, early diagnosis and targeted therapy. Preventative measures focus on minimising microbial colonisation through care bundles that include elevation of the head of bed, strict hand hygiene, oral antisepsis and subglottic secretion drainage. Selective decontamination of the digestive tract has been investigated as a means to reduce pathogenic overgrowth without promoting antimicrobial resistance. Diagnostic challenges arise from the absence of a universally accepted gold standard; clinical signs, radiology and microbiological cultures each carry limitations. Emerging surveillance paradigms advocate monitoring ventilator settings to detect complications more objectively. Once VAP is suspected, bronchoalveolar lavage or tracheal aspirates guide empirical antibiotic selection, which is then refined by culture results and local resistance patterns. Antimicrobial stewardship is central to optimising antibiotic duration and spectrum, reducing resistance and improving outcomes. Recent efforts emphasise harmonisation of diagnostic criteria across trials, incorporation of rapid biomarker assays and integration of novel prevention technologies to strengthen global responses to VAP.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Ventilator-Associated Pneumonia Management Strategies publication trend

The graph below shows the total number of articles in ventilator-associated pneumonia management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Ventilator-associated pneumonia (VAP): Pneumonia developing more than 48 hours after endotracheal intubation and mechanical ventilation.

Selective decontamination of the digestive tract (SDD): Application of non-absorbable antibiotics to the oropharynx and gut to suppress pathogenic flora.

Care bundle: A set of evidence-based preventive measures applied together to reduce ventilator-associated complications.

Bronchoalveolar lavage (BAL): Procedure in which sterile fluid is instilled into the lower airways and retrieved for microbiological and biomarker analysis.

Antimicrobial stewardship: Coordinated interventions designed to optimise antibiotic use, improve patient outcomes and limit resistance.

References

1. Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study). Gut (2024).
2. Unravelling the complexity of ventilator-associated pneumonia: a systematic methodological literature review of diagnostic criteria and definitions used in clinical research. Critical Care (2024).
3. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infection Control and Hospital Epidemiology (2022).
4. Multicenter Evaluation of a Novel Surveillance Paradigm for Complications of Mechanical Ventilation. PLOS ONE (2011).
5. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. The Lancet Respiratory Medicine (2019).